DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Phase: N/A

Status: Completed

Sponsored by: Merck Sharp & Dohme Corp.

Summary

This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12. 5 mg [Hyzaar(R)]) treatment for a period of at least three months on serum uric acid levels.

Clinical Details

Official title: A Retrospective Survey to Evaluate the Impact of Hyzaar on Uric Acid in the Management of Hypertensive Patients in Normal Practice

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome: Serum Uric Acid (SUA) Level

Secondary outcome:

The Percentage of Patients With Hyperuricemia

Diastolic Blood Pressure (DBP)

Systolic Blood Pressure (SBP)

Eligibility

Minimum age: 20 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion criteria:

- Participant was >20 years and <75 years of age on the index date (i. e., the date of

initiating MK-0954A therapy)

- Diagnosed with hypertension and had received MK-0954A 50/12. 5 mg for at least 3

months

- Had at least one serum uric acid measurements at baseline and one at 3 months after

using MK-0954A 50/12. 5 mg

- Had the following records documented in the chart during the data collection period:

- medical history and co-morbidities (if available)

- sitting blood pressure, serum uric acid, lipid profile test results before and

after using MK-0954A 50/12. 5 mg

- serum electrolytes, serum creatinine, and pre-meal sugar (if available)

- prescription information of all antihypertensive regimens

Exclusion criteria:

- Had been treated with diuretic or angiotensin-receptor blockers (ARBs) 2 weeks before

initiated treatment with MK-0954A 50/12. 5 mg

- Serum creatinine >2 mg/dL

Locations and Contacts

Additional Information

Starting date: November 2008
Last updated: December 3, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017